Guest guest Posted November 30, 2007 Report Share Posted November 30, 2007 Glaxo asthma drug needs kid risk warning-FDA panel By Kim Dixon Thursday, November 29, 2007; 4:27 AM GAITHERSBURG, Md. (Reuters) - U.S. regulatory advisers on Wednesday recommended strengthening safety warnings on GlaxoSmithKline Plc's asthma drug Serevent amid new reports of deaths in children taking the drug....... .........The data is very troubling because both the increase in hospitalization and in mortality is so different " from what doctors currently believe, said Thomas Newman, an epidemiologist at the University of California, San Francisco, and panel member........ ........At least two panel members said the data was so convincing that Serevent should be pulled from the market. The FDA said it will consider the safety of all drugs in the class, called long-acting beta agonists, at a future meeting.... http://www.healthcentral.com/allergy/news-196410-66.html Will the FDA move on this drug . Probably not. Thanks Vince Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.